

---

## Lipigon (Q3 Review) - Topline Before Year-End

Redeye comments on Lipigon's Q3 report. The topline readout of the ongoing phase IIa study of Lipisense in Q4 2025 will be a major catalyst and inform future developments.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Lipigon (Q3 Review) - Topline Before Year-End**